Global /China /Healthcare /Medical Devices /9877
chevron_leftBack
Jenscare Scientific Co., Ltd. logo

Jenscare Scientific Co., Ltd.

9877
SHEK: 9877 Delayed
9.78HKD 1%
1.25 USD
As of 13 June 2026, Jenscare Scientific Co., Ltd. has a market cap of $515.25M USD, ranking #14926 globally and #4647 in China. It ranks #1328 in the Healthcare sector, and #271 in the Medical Devices industry.
Global Rank
14926
Country Rank
4647
Sector Rank
1328
Industry Rank
271
Key Stats
Market Cap
$515.25MUSD
4.04B HKD
Enterprise Value
$444.78MUSD
3.49B HKD
Revenue (TTM)
$12.86MUSD
100.81M HKD
EBITDA (TTM)
-$31.28MUSD
-245.19M HKD
Net Income (TTM)
-$38.51MUSD
-301.83M HKD
EBITDA Margin
-243%
Profit Margin
-299%
PS Ratio
40.1
PB Ratio
4.7
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Medical Devices
CEO
Fei Pan open_in_new
Employees
195
Founded
2011
Website
jenscare.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
1% -1.9% 0.2% 20% -6.9% 59%

News

Loading...

Markets

Exchange Ticker Price
Hong Kong Stock Exchange
MIC: XHKG
PRIMARY
9877
宁波健世科技股份有限公司 Class H
ISIN: CNE100005KC9
Shares Out.:
310.243M1 Shares Float: 120.74M2
TV:
SA:
YF:
GF:
BA:
MS:
9.78 HKD
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Jenscare Scientific Co., Ltd.

Jenscare Scientific Co., Ltd., a medical device company, engages in the research and development of interventional products for the treatment of structural heart diseases in the People’s Republic of China. It offers LuX-Valve and LuX-Valve Plus, a transcatheter tricuspid valve replacement (TTVR) product for the treatment of severe tricuspid regurgitation and high surgical risk; KenFlex, a transcatheter aortic valve intervention (TAVR) repair system product for the treatment of aortic valve regurgitation; and Ken-Valve, a TRVR system for the treatment of severe aortic regurgitation or combined with aortic stenosis. The company also develops JensClip, a clip-based transcatheter mitral valve intervention (TMVR) repair system to treat patients with severe mitral regurgitation; JensRelive, a TMVR system to treat patients with severe mitral regurgitation and replace dysfunctional primary mitral valves without undergoing routine thoracotomy surgery; and SimuLock, a bionics left atrial appendage occluder system for cardiogenic stroke prevention. In addition, it offers platform technologies/accessories comprising introducer kit, JeniGal anti-calcification technology, dry-tissue technology and polymer leaflet technology; and engages in consulting and investment activities. The company was incorporated in 2011 and is headquartered in Ningbo, the People’s Republic of China.

Similar Companies

Industry: Medical Devices (China)
Name
Market Cap diff.
PE
$30.06B
203.66B CNY
6K%
26.0
$13.61B
92.23B CNY
3K%
48.5
$5.61B
38.02B CNY
989%
23.4
$5.52B
37.43B CNY
972%
52.7
688617
$5.04B
34.14B CNY
878%
39.6
$4.55B
30.86B CNY
784%
13.7
Industry: Medical Devices (Global)
Name
Market Cap diff.
PE
$173.27B
34K%
25.8
$160.73B
31K%
56.7
$159.07B
31K%
25.6
DHR
$126.55B
24K%
34.7
SYK
$120.69B
23K%
38.3
MDT
$101.9B
20K%
22.2
chevron_leftBack